Always tough to identify an inflexion point in advance, especially with a biotech but ultimately it comes down to sales and regulatory approvals.
Last quarter sales were disappointing but all it takes is a quarter or two of significant growth and people are pretty quick to do the math on the compounding. Hopefully this quarter growth is sufficient to make the numbers look compelling.
Ann: Part 1 Remplir US Market Authorisation Successfully Complete, page-33
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.3¢ |
Change
-0.003(0.65%) |
Mkt cap ! $80.06M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 38.3¢ | $15.96K | 41.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 40915 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 13194 | 2 |
View Market Depth
| Last trade - 14.19pm 30/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |